Phase II Study of Sequential Topotecan and Etoposide in Patients with Intermediate Grade Non-Hodgkin's Lymphoma: A National Cancer Institute of Canada Clinical Trials Group Study-Reference-Cited by-同舟云学术

Phase II Study of Sequential Topotecan and Etoposide in Patients with Intermediate Grade Non-Hodgkin's Lymphoma: A National Cancer Institute of Canada Clinical Trials Group Study

Published:2002-01 Issue:8 Volume:43 Page:1581-1587
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Crump Michael,Couban Stephen,Meyer Ralph,Rudinskas Leona,Zanke Brent,Gluck Stefan,Maksymiuk Andrew,Hoskins Paul,Matthews Sarah,Eisenhauer Elizabeth

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/1042819021000002901

Reference34 articles.

1. Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma

2. Comparison of a Second-Generation Combination Chemotherapeutic Regimen (m-BACOD) with a Standard Regimen (CHOP) for Advanced Diffuse Non-Hodgkin's Lymphoma

3. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.

4. LONG-TERM FOLLOW-UP OF PLATINUM-BASED LYMPHOMA SALVAGE REGIMENS

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Topotecan combined with Ifosfamide, Etoposide, and l-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma;Medical Oncology;2014-11-27

2. A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up;Bone Marrow Transplantation;2012-03-19

3. Comeback for the camptothecins?;Leukemia & Lymphoma;2009-10-08

4. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551;Cancer Chemotherapy and Pharmacology;2008-07-23

5. Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone);Annals of Hematology;2008-06-28